

For Immediate Release January 11, 2012

## **Bolton Medical Announces Completion of patient enrollment for the ADVANCE Clinical Study**

Barcelona, ES---Bolton Medical announced it has completed enrollment of its ADVANCE European Clinical Study to evaluate the safety and efficacy of the Treovance Abdominal Stent-Graft with Navitel Delivery System for use in endovascular aortic repair (EVAR) of abdominal aortic aneurysms. Physicians at five hospitals across Europe have enrolled thirty patients. The final case was performed by Dr. Vicente Riambau at Hospital Clinic of Barcelona, Spain.

“The Bolton ADVANCE study has been completed and so far the device shows promising results”, said Prof. Roberto Chiesa, Principal Investigator for the ADVANCE Study “I think that the Treovance Abdominal Sten-Graft continues a new generation of devices focused on providing: low-profile systems, precise deployment, stent-graft repositioning and additionally offers features to minimize late disconnections”

With its accurate deployment, flexible design, multiple fixation points and wide range of sizes, the Treovance Abdominal Stent-Graft offers many advantages to EVAR patients. The low profile Navitel Delivery System is equipped with a detachable sheath and allows for controlled or rapid deployment of the Treovance Abdominal Stent-Graft. The Study included thirty patients from five facilities throughout Europe. Prof. Gioacchino Coppi (Nuovo Ospedale di St. Agostino-Estense, Modena, Italy), Dr. Burkhardt Zipfel (Deutsches Herzzentrum Berlin, Germany) and Dr. Secundino Llagostera - Dr. Carlos Esteban (Hospital German Trias i Puyol, Badalona, Spain) complete the list of investigators participating in the study.

For more information on the Treovance device and clinical trial, please visit [www.treovance.com](http://www.treovance.com)

### **COMPANY**

Bolton Medical currently manufactures Relay Plus and Relay NBS Plus Thoracic Stent-Grafts. They are indicated for the treatment of main thoracic aortic pathologies such as aneurysms, penetrating ulcers, pseudoaneurysms, and intramural hematomas in International Market. To date, approximately 6,000 **Relay and Relay NBS** Stent-Grafts have been implanted worldwide. Bolton anticipates US FDA approval of Relay in 2012. For more information on Relay U.S. trial, please visit [www.relayclinicaltrial.com](http://www.relayclinicaltrial.com).

Bolton Medical is a private company, with European operations based in Barcelona, Spain, and U.S. operations in Sunrise, Florida. Bolton Medical is a wholly-owned subsidiary of the Werfen Life Group, a diverse manufacturer and supplier of products for the medical industry.

[www.boltonmedical.com](http://www.boltonmedical.com)

Public Relations Contacts:

USA: Candace DeLeonardis 1-727-692-0283

International: Carlos Camps +34 93.817.63.10

-- END --